Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

Bullboard Posts

Comment by GObabyGO1on May 07, 2020 11:56pm

95 Views

Post# 31001391

RE:Tomorrow

Management isn't that stupid. If they did that they would lose all credibility. They screwed up with amending it once already. It would be bonkers if they amended the PP again. As long as the data is positive from the trials, the sky is the limit. The Korean trial starts tomorrow and will set the tone going forward. If it's a flop all other trials may be pointless. Next 2-3 weeks are critical!

Bullboard Posts

Pro Women’s Hockey League comes to NHL 25 in December